Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

UNCOVERED: 17 - Caught on Camera

Novo Nordisk: A New Boost for GLP-1 Sales on the Horizon

Novo Nordisk A/S is moving closer to adding more sales for its blockbuster GLP-1 drug semaglutide to treat a chronic liver disease.

MarketBeat

3 Healthcare Stocks to Buy Now for a Healthy Portfolio in 2025

The healthcare industry is set for growth due to the growing demand for quality treatments and ongoing progress in medical technology. Hence, investors might consider investing in healthcare stocks, Eli Lilly (LLY), Thermo Fisher Scientific (TMO), and Abbott Laboratories (ABT) for a healthy portfolio in 2025. Read more….

StockNews.com

Eli Lilly To Invest $3B To Expand Plant To Meet Surge In Demand For Weight Loss Drugs

Construction on the facility in Kenosha County, Wis., is expected to begin next year.

International Business Times

From analysis to the latest developments in health,
read the most diverse news in one place.

Eli Lilly Invests Billion In Manufacturing Expansion Projects

Eli Lilly invests billion to boost manufacturing capabilities, expanding in Wisconsin and Indianapolis to meet growing market demand.

Top News

2 Telehealth Stocks That Could Gain from Trump’s New FDA Pick

Discover two telehealth stocks, Hims & Hers (HIMS) and Teladoc (TDOC), poised to benefit from Trump's FDA nominee, Dr. Marty Makary, a telemedicine advocate.

MarketBeat

Read news from The Economist, FT, and more,
with one subscription

Obese people ‘will have to wait’ for weight loss jab Mounjaro, NHS officials warn

Mounjaro to be rolled out to only patients with the highest needs, the NHS has said

The Independent UK

Obese people ‘will have to wait’ for Mounjaro amid carefully managed NHS rollout

The decision will help ‘protect other vital NHS services’.

The Independent UK

Weight-loss meds go head-to-head in new study. One was significantly more effective, drugmaker says

In the first head-to-head test, people using Eli Lilly’s Zepbound lost just over 50 pounds while those using competitor Novo Nordisk’s Wegovy shed more than 33 pounds

The Independent UK

Stock Of The Day: Where Will The Eli Lilly Rally End?

Shares of Eli Lilly (LLY) are approaching a price level that had previously been a peak. There is a good chance they hit resistance at it.

Benzinga

Decoding Eli Lilly's Options Activity: What's the Big Picture?

Investors with a lot of money to spend have taken a bearish stance on Eli Lilly (NYSE:LLY).

Benzinga

Is Eli Lilly Stock Outperforming the S&P 500?

Eli Lilly has outperformed the S&P 500 over the past year, and analysts are highly optimistic about the stock’s prospects.

Barchart

Better drugs through AI? Insitro CEO on what machine learning can teach Big Pharma

Artificial intelligence is changing the way industries do business

The Independent UK

Get all your
news in one place.

100's of premium titles.
One news app.

Barchart

3 Mega-Cap Stocks to Buy Before They're Worth $1 Trillion

These corporate giants could be the next entrants to the $1 trillion market cap club.

StockNews.com

Eli Lilly (LLY) vs. Catalent (CTLT): Which Pharma Stock Offers Better Returns?

The pharma industry is evolving rapidly due to the ever-rising healthcare needs and increasing demand for customized medicine and treatments worldwide. So, let’s analyze Eli Lilly (LLY) and Catalent (CTLT), to determine which pharma stock offers better returns. Read more.

Benzinga

Behind the Scenes of Eli Lilly's Latest Options Trends

Financial giants have made a conspicuous bearish move on Eli Lilly. Our analysis of options history for Eli Lilly (NYSE:LLY) revealed 8 unusual trades.

MarketBeat

Eli Lilly, Pfizer, and AstraZeneca: 2025 Vaccine Makers to Watch

Here's why Eli Lilly, Pfizer, and AstraZeneca are biotech stocks worth considering, with strong pipelines and growth potential beyond vaccines.

Get all your
news in one place.

100's of premium titles.
One news app.

Fortune

Novo Nordisk Foundation CEO dismisses ‘Nokia risk’ to Denmark’s economy

Novo Nordisk Foundation CEO Mads Krogsgaard Thomsen said only 9 million people are using GLP-1s compared with 1 billion people living with obesity.

Barchart

2 Vaccine Stocks to Buy on the Dip

Given the cutting-edge pipeline for these two vaccine companies, double-digit slumps in these stocks present a compelling entry point for investors.

International Business Times

Weight-Loss Drugmakers Press Companies To Cover Cost Of Treatment

The efforts by Eli Lilly and Novo Nordisk could be a game-changer for sales, which some analysts say could exceed $100 billion a year.

Barchart

Buy This Pharma Stock to Bet on the Next Blockbuster Weight-Loss Drug

A shocking study in The Lancet showed that nearly three-quarters of U.S. adults are overweight or obese. Chances are that by 2050, there will be 260 million overweight Americans. We already have GLP-1 drugs, and amylin-based drugs are next. Novo Nordisk's compound, Cagrilintide, will be combined with semaglutide in its…

International Business Times

Lilly Sues US Agency For Blocking Proposed Drug Rebate Plan

Eli Lilly is taking the HRSA to court for allegedly blocking the pharma's discount plan.

Al Jazeera

Could weight loss drugs fix UK’s unemployment problem?

US pharmaceuticals group Eli Lilly is to conduct trials of its weight-loss drugs in the UK.

Fortune

Eli Lilly CEO's explains how failing fast leads to success

For Eli Lilly CEO Dave Ricks, speeding up the drug discovery process is essential to success.

1 … 16 17 18 19

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Artificial Intelligence

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.